BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026
MWN-AI** Summary
BioStem Technologies® (OTC: BSEM), a prominent player in regenerative medicine, is set to showcase its innovations and clinical evidence at the Symposium on Advanced Wound Care (SAWC) Spring meeting in Charlotte, NC, from April 8-12, 2026. The event, which brings together leading clinicians, researchers, and professionals in wound care, serves as a platform for BioStem to highlight its expanded product offerings, including the newly launched Neox Product line.
Chairman and CEO Jason Matuszewski expressed pride in contributing to the clinical dialogue at SAWC, emphasizing the Neox line as a significant addition to BioStem's portfolio of perinatal tissue allografts. This expansion allows for a broader range of therapeutic options tailored to diverse clinical needs and site care requirements. The focus remains on enhancing patient outcomes through innovative products supported by robust clinical data. BioStem’s offerings, backed by substantial randomized clinical trials and real-world evidence, underline its commitment to being a leader in the regenerative medicine market.
During the symposium, BioStem will host a lunch symposium titled "A New Season in Wound Care: An Expanded Portfolio Grounded in Evidence," featuring esteemed speakers such as Dr. Wendy Weston and William Marston, MD. This session will cover the newly expanded product line and present findings from a randomized controlled trial on diabetic foot ulcers, concluding with a Q&A segment for attendees.
BioStem will also present a scientific poster, available for viewing in Exhibit Hall 1C, signifying the company's dedication to clinical research and medical education. By enhancing access to advanced healing technologies, BioStem aims to improve care across various healthcare settings, continuing its mission of innovation in regenerative medicine.
MWN-AI** Analysis
As BioStem Technologies (OTC: BSEM) gears up for its participation in the Symposium on Advanced Wound Care, analysts should take note of the company's robust positioning in the regenerative medicine market, particularly its focus on perinatal tissue allografts. The introduction of the Neox product line underscores BioStem's commitment to expanding its product portfolio and providing differentiated wound care options tailored to clinical needs.
Investors should focus on several key factors influencing BioStem’s potential trajectory. Firstly, the company’s participation in a high-profile industry symposium highlights its focus on engagement and education within the medical community. The planned discussions and presentations by industry experts promise to underscore the scientific foundation supporting BioStem's offerings, particularly recent randomized clinical trials demonstrating efficacy in diabetic foot ulcers. Such evidence could strengthen clinician trust, thereby driving adoption rates.
Additionally, BioStem’s proprietary processing technologies, including BioRetain, CryoTek, and SteriTek, suggest a commitment to quality and innovation, critical for sustaining competitive advantage in the regenerative medicine space. The quality management system accredited by the American Association of Tissue Banks also enhances credibility, which is vital in a sector heavily scrutinized for safety and efficacy.
Short-term, investors should look for potential volatility around the conference dates, as announcements can influence stock performance. Long-term, increasing adoption of advanced wound care therapies and BioStem's efforts in expanding its clinical research initiatives should bode well for sustained revenue growth. With a national footprint and increasing visibility through strategic presentations, BioStem represents an intriguing opportunity in the regenerative medicine sector. Investors should watch for developments post-symposium, including clinician feedback and any new partnerships or collaborations that may arise.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
POMPANO BEACH, Fla., April 08, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies® (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing and commercialization of perinatal tissue allograft products, today announced its participation in the Symposium on Advanced Wound Care (SAWC) Spring meeting in Charlotte, NC, from April 8-12. SAWC is one of the premier gatherings for wound care professionals, clinicians, and researchers.
“We are proud to contribute to the ongoing clinical dialogue at SAWC, where leading minds in wound care come together,” said Jason Matuszewski, Chairman and CEO of BioStem Technologies. “During this Spring Session, we will be highlighting our recently introduced Neox Product line, which is now part of BioStem Technologies’ family of perinatal tissue. This addition of Neox, expands our capabilities across multiple tissue formats, provides physicians with differentiated options depending on the clinical need, handling preferences and site of care requirements, and reinforces our focus on advancing science and equipping clinicians with the data and tools they need to improve patient outcomes. Our expanded portfolio, offers the most comprehensive suite of placental and umbilical cord tissue solutions, backed extensively by both randomized clinical trials and real-world evidence, and we are pleased to showcase BioStem’s leadership in this market.”
Booth Schedule (all times EST):
| 5:30 PM – 7:30 PM 11:30 AM – 2:00 PM 11:30 AM – 2:00 PM |
In addition to its booth schedule during show exhibit hours, BioStem is hosting a lunch symposium for attendees and introducing an accepted scientific poster.
Innovation Theater Lunch Symposium:
A New Season in Wound Care: An Expanded Portfolio Grounded in Evidence is taking place on Thursday, April 9th, from 12:15p.m. to 1:45p.m. in Room 207C. Featuring:
- Dr. Wendy Weston, PhD, CTBS
- William Marston, MD
- Herbert Slade, MD
The luncheon will include a discussion of several key topics, including an introduction to the newly expanded BioStem Technologies product portfolio, the science behind its innovative suite of birth tissue products, the recently published results of a randomized controlled trial on diabetic foot ulcers and practical guidance on how to incorporate these therapies into clinical practice. The session will conclude with a live question-and-answer session.
Accepted Poster Presentation:
BioStem will present a new scientific poster presentation, which will be available for viewing in Exhibit Hall 1C. Poster number is LR-020. BioStem’s participation demonstrates its continued investment in clinical research and medical education as it works to expand access to advanced healing technologies across a wide range of care settings. Attendees interested in learning more about BioStem’s technologies and clinical data are encouraged to attend the luncheon session and visit the company’s poster presentation and booth during the conference.
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies® is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Clinicians across a wide range of specialties use its allografts. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.
BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.
Contact BioStem:
Website: www.biostemtechnologies.com
E-Mail: pr@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342
Investor Relations:
Philip Trip Taylor, Gilmartin
Group E-Mail: ir@biostemtech.com
Public Relations:
Jennifer Horton, Relevance
jennifer@relevance.com
FAQ**
How does BioStem Technologies Inc BSEM plan to leverage the outcomes of its randomized controlled trial on diabetic foot ulcers to enhance its market position in regenerative medicine?
What specific advancements in the newly introduced Neox Product line does BioStem Technologies Inc BSEM expect to showcase at the SAWC Spring meeting?
In what ways is BioStem Technologies Inc BSEM reinforcing its commitment to clinical research and education within the wound care community through its participation at SAWC?
Can BioStem Technologies Inc BSEM provide details on the clinical efficacy of its product portfolio, particularly the Neox® brand, in improving patient outcomes?
**MWN-AI FAQ is based on asking OpenAI questions about BioStem Technologies Inc (OTC: BSEM).
NASDAQ: BSEM
BSEM Trading
-2.19% G/L:
$3.97 Last:
29,449 Volume:
$4 Open:
